A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci, Peter, Brunner, Harald, Laferl, Hermann, Scherzer, Thomas-Matthias, Maieron, Andreas, Strasser, Michael, Fischer, Gabriele, Hofer, Harald, Bischof, Martin, Stauber, Rudolf, Gschwantler, Michael, Steindl-Munda, Petra, Staufer, Katharina and Löschenberger, Karin (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology (Baltimore, Md.), 47 (6). pp. 1816-23. ISSN 1527-3350

Full text not available from this repository.

Item Type:	Article
Divisions:	Ordensklinikum Linz Elisabethinen > Interne 4 - Gastroenterologie & Hepatologie, Stoffwechsel & Ernährungsmedizin, Endokrinologie
Depositing User:	Prof. Dr. Rainer Schöfl
Date Deposited:	29 Oct 2019 12:32
Last Modified:	17 Feb 2025 09:33
URI:	https://eprints.vinzenzgruppe.at/id/eprint/8821

Edit Item